@article{JGO14902,
author = {Nadia A. Saeed and Eric A. Mellon and Kenneth L. Meredith and Sarah E. Hoffe and Ravi Shridhar and Jessica Frakes and Jacque-Pierre Fontaine and Jose M. Pimiento and Nishi Kothari and Khaldoun Almhanna},
title = {Adjuvant chemotherapy and outcomes in esophageal carcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: Standard treatment for locally advanced esophageal cancer is neoadjuvant chemoradiation followed by surgery. The role of postoperative chemotherapy is unclear. We sought to determine the indications, patterns, and outcomes for adjuvant chemotherapy in esophageal carcinoma.
Methods: This single institution retrospective review included patients with esophageal cancer who received neoadjuvant chemoradiation and surgery at Moffitt. We identified patients in this cohort who additionally received adjuvant chemotherapy. Medical records were reviewed for demographic/clinical information. Survival was estimated using the Kaplan-Meier method and compared by log-rank. Case-control analysis was performed using a 2:1 nearest neighbor propensity score matching algorithm, which included 92 without adjuvant chemotherapy and 46 with adjuvant chemotherapy.
Results: We identified 382 patients, 46 of whom received adjuvant chemotherapy. Patients who received adjuvant chemotherapy were younger (60.2 vs. 63.8 years; P=0.047), more likely to have adenocarcinoma (91% vs. 85%; P=0.034), had more advanced ypT and ypN classifications (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/14902}
}